EZH2 mutations have been identified as a driver for relapsed DLBCL [52], with increased frequencies in matched diagnosis-relapse analysis [44,51], and independent R/R DLBCL cohorts [25,34,44]. Here, EZH2 is linked to diffuse large B-cell lymphoma.